Efficacy of ganglioside combined with hyperbaric oxygen therapy in the treatment of cerebral hemorrhage
10.3760/cma.j.cn341190-20240703-00855
- VernacularTitle:神经节苷脂联合高压氧治疗脑出血49例疗效观察
- Author:
Yue LIU
1
;
Haiyan SONG
1
;
Xianli WANG
1
;
Ting LI
1
Author Information
1. 巴彦淖尔市医院神经内一科，巴彦淖尔 015000
- Publication Type:Journal Article
- Keywords:
Cerebral hemorrhage;
Gangliosides;
Hyperbaric oxygenation;
Brain edema;
Chemokines;
High mobility group proteins;
Cranial nerve injuries
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(1):37-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the therapeutic effect of ganglioside combined with hyperbaric oxygen in the treatment of cerebral hemorrhage. To investigate the effects of ganglioside combined with hyperbaric oxygen therapy on serum inflammatory factors and neural injury markers in patients.Methods:A randomized controlled study was conducted involving 98 patients with cerebral hemorrhage treated at Bayannur Hospital from January 2022 to January 2024. The patients were randomly assigned to either a control group or a combination group, with 49 cases in each group, using a random number table method. All patients received routine treatment. The control group received hyperbaric oxygen therapy, while the combination group received both hyperbaric oxygen therapy and ganglioside therapy. Both groups were treated for 20 days. The volume of cerebral edema, levels of serum inflammatory factors, and neural injury markers were compared between the two groups before and after treatment, and the efficacy of both groups was evaluated.Results:After treatment, the brain edema volume in the combination group [(12.31 ± 1.31) cm3]was significantly lower than that in the control group [(15.36 ± 1.62) cm3, t = 10.25, P < 0.05]. The Glasgow Coma Scale score in the combination group [(13.64 ± 1.37) points] was significantly higher than that in the control group [(11.42 ± 1.24) points, t = -8.41, P < 0.05]. The serum levels of interleukin-1β and interleukin-8 in the combination group were (5.48 ± 0.56) ng/L and (12.29 ± 1.33) ng/L, respectively, both of which were significantly lower than those in the control group [(6.42 ± 0.67) ng/L, (16.85 ± 1.71) ng/L, t = 7.54, 14.74, both P < 0.05]. The levels of soluble protein-100β (S100β) and high mobility group protein-1 in the combination group were (0.62 ± 0.07) μg/L and (4.17 ± 0.42) μg/L, respectively, both of which were significantly lower than those in the control group [(0.81 ± 0.09) μg/L, (5.59 ± 0.56) μg/L, t = 11.67, 14.20, both P < 0.05]. The National Institutes of Health Stroke Scale score in the combination group [(11.47 ± 1.23) points]was significantly lower than that in the control group [(15.31 ± 1.62) points, t = 13.22, P < 0.05]. The Fugl-Meyer Assessment of Motor Recovery after Stroke score in the combination group [(63.58 ± 6.48) points] was significantly higher than that in the control group [(54.64 ± 5.71) points, t = -7.25, P < 0.05]. The total response rate in the combination group was 91.84% (45/49), which was significantly higher than that in the control group [73.47% (36/49), χ2 = 5.76, P < 0.05]. Conclusions:The use of gangliosides in combination with hyperbaric oxygen therapy for the treatment of cerebral hemorrhage can effectively reduce cerebral edema, lessen inflammatory responses, and minimize neural injury. This approach helps restore patients' neurological and motor functions and enhance overall treatment efficacy.
